Global Migraine Drugs Market is Expected to Reach $8.2 bn by 2026

The Global Migraine Drugs Market was valued at US$3.9 billion in the year 2018 and is expected to reach US$8.2 billion by 2026, at a CAGR of 9.73%.

Migraine Drugs are a group of medication that is given for the relief of symptoms associated with migraine pain. Around 18 to 19 % of the global populace complain of frequent chronic headaches. In the UK alone, the reported cases of migraine headaches each day extends to about 190,000, which is considered very high. The incidence of migraine peaks between 15 and 24 years of age, wherein the prevalence is high among individuals aged between 35 and 45 years. Out of this, women are more vulnerable to acquire migraine headaches in comparison to the male population.

As per the Migraine Association of Ireland, the proportion of female to male migraineurs was observed to be 3:1. This increased proportion is due to the variations in the estrogen levels during menstruation. This rising instance of migraine among the female populace is set to drive the development of a migraine drug market in the region.

Rise in the female population, the introduction of calcitonin gene-related & peptide-based therapies, a surge in awareness among the patients related to prevention & treatment and improved uptake of novel drug classes are boosting the migraine drugs market. Also, the FDA has approved several drugs such as Aimovig for the prevention of chronic migraines, which may provide promising opportunities for the progress of the migraine drug market. However, side-effects and risks that are associated with these new-generation drugs may hamper the market growth.

Allergan's Botox was in a solid focused position in the preventive migraine market. As the main endorsed medication, Botox significantly covers around 60.0% of the market share. However, Botox is expected to face rivalry from launch of Amgen/Novartis' Aimovig which engrossed around US$ 59 million in 2019 Q1 sales and which is expected to reach more than US$ 1billion at the end of 2022and other exceptionally viable CGRP-based treatments, which targets both chronic and episodic migraine, unlike Botox, which is only approved for the chronic variant of the condition.

Companies such as Pfizer Inc., GlaxoSmithKline plc, Allergan plc, Amgen Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Biohaven Pharmaceutical, Johnson and Johnson, and Bausch Health Companies Inc, etc., are also keen on launching their migraine drugs depending upon the competition, pricing of the competitors, etc.

Optima Insights had classified the migraine drug market based on the route of administration, therapeutic class, treatment class, and regions. The oral segment engrossed maximum revenue when compared to the injectable segment. Especially, drugs such as oral diclofenac potassium 50 mg are successful in treating the intense headache.

The CGRP antagonists and antibodies are said to dominate the overall market share with maximum revenue generation in the upcoming years. Because of R&D activities, for example, nitrous oxide inhibition, corticotrophin receptor antagonism, and CGRP-based receptor and ligand inhibition. Approval of CGRP monoclonal antibodies is one of the key advancements in the preventive market. The CGRP inhibitor propelled in Europe in July 2018 and North America during May 2018 and has received a positive reaction from patients and healthcare providers.

Eli Lilly's Emgality (galcanezumab) also received FDA endorsement in October 2018. In September 2018, Teva's Ajovy (fremanezumab) turned into the second CGRP treatment to be approved by the FDA for headache prevention. Ajovy is the sole CGRP monoclonal therapeutic acting agent that gives patients quarterly and monthly dosing alternatives.

The abortive drugs are utilized more in controlling the severity of migraine headaches and also to reduce the frequency of its occurrence. This is one of the reasons why physicians prescribe more abortive drugs as these medications work best when taken during the initial stages of migraine development. These factors are said to drive the market share during the forecast period from 2019 to 2026.

In North America, the United States alone comprises of around 37 million migration population that accounts for nearly 65% of the worldwide populace. This migraine population is said to increase at a constant pace and contribute to market growth. Also, the territorial market will benefit to a greater extent due to the dispatch of calcitonin gene-related peptide-based treatments                                                                                          

Companies such as Amgen Inc, Eli Lilly, and Company, Novartis International AG, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd, Allergan plc, etc. are witnessing a shift in terms of strong R&D with the introduction of CGRP-based therapies like ubrogepant and atogepant.

The Migraine Drug Market Outlook 2019-2026, from Optima Insights, will offer a thorough insight on the market growth till the forecast year 2026 based on the market segmentation (Type, Process, End-Use, and Region). The report also comprises comprehensive profiling of companies involved in Migraine Drug, product information, and pipeline information.

The Report Provides Key Insights on

  • History of the Migraine Drug Market, 2015 to 2017

  • Forecast of the Migraine Drug Market Growth till the year 2026

  • The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Migraine Drug Market

  • Analysis of potential growth segments which will drive the market

  • Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market

  • Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics

Request for sample pages @

Migraine Drugs Market Based on Route of Administration (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

  • Injectables

  • Oral

Migraine Drugs Market Based on Therapeutic Class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

  • Triptans

  • Ergot

  • NSAIDs

  • CGRP antagonists and antibodies

Migraine Drugs Market Based on Treatment Class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

  • Abortive

  • Prophylactic

Migraine Drugs Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

  • North America

  • Europe

  • APAC


Migraine Drugs Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)

  • Eli Lilly and Company

  • Teva Pharmaceutical Industries Ltd

  • Novartis AG

  • Amgen

  • Allergan plc

Download Complete TOC of the Report @

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.


Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)